Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vion Submits Laromustine For Use In Niche Population

This article was originally published in The Pink Sheet Daily

Executive Summary

Vion takes the quickest path to market for laromustine, now Onrigin, by submitting an NDA for use in elderly patients with poor prognosis.

You may also be interested in...



FDA Hold On Cloretazine Phase III Trial Is Lifted, Putting Vion On Track For 2008 NDA

Company concedes it could run out of cash in 2009 if cancer drug is not commercialized.

Vion Suspends Cloretazine Phase III Enrollment In Leukemia Patients

Suspension is a “hiccup” but development of the alkylating agent for adult myelogenous leukemia will move forward, Vion CEO Kessman states.

Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?

Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel